Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 4/20 | 0.46 |
| ▸ | NPC1 | O15118 | 4/20 | 0.46 |
| ▸ | ESR1 | P03372 | 2/20 | 0.41 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | DAO | P14920 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | SLC8A1 | P32418 | 7/20 | 0.34 |
| ▸ | LTA4H | P09960 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19301933 | 0.91 | RAB9A (0.46) | RAB9ANPC1ESR1ESR2KMT2A | |
| SCHEMBL19301952 | 0.81 | RAB9A (0.59) | RAB9ANPC1ESR1ESR2KMT2A | |
| SCHEMBL22221860 | 0.80 | RAB9A (0.53) | RAB9ANPC1ESR1ESR2KMT2A | |
| SCHEMBL19492442 | 0.79 | ALOX15 (0.47) | RAB9ANPC1ESR1ESR2DAO | |
| SCHEMBL24317806 | 0.77 | RAB9A (0.45) | RAB9ANPC1ESR1ESR2KMT2A | |
| SCHEMBL24317809 | 0.76 | RAB9A (0.46) | RAB9ANPC1ESR1ESR2KMT2A | |
| SCHEMBL24317254 | 0.74 | DAO (0.34) | DAO | |
| SCHEMBL19841171 | 0.72 | ALOX15B (0.44) | RAB9ANPC1ESR1ESR2 | |
| SCHEMBL18896907 | 0.70 | LTA4H (0.37) | LTA4H | |
| SCHEMBL19492455 | 0.70 | ALOX15 (0.45) | RAB9ANPC1ESR1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11077046-B2 | Gamma-diketones for treatment and prevention of aging skin and wrinkles | BIOSPLICE THERAPEUTICS, INC. (US) | 2021-08-03 | — | — | US | disclosed |
| US-20200222295-A1 | GAMMA-DIKETONES FOR TREATMENT AND PREVENTION OF AGING SKIN AND WRINKLES | MED-PATHWAYS II LIMITED (VG) | 2020-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11077046-B2 | Gamma-diketones for treatment and prevention of aging skin and wrinkles | GLA, DGKG, DGKA | RAB9A 2923/4885NPC1 4073/4885ESR1 4332/4885 |
| US-20200222295-A1 | GAMMA-DIKETONES FOR TREATMENT AND PREVENTION OF AGING SKIN AND WRINKLES | GLA, DGKG, DGKA | RAB9A 2923/4885NPC1 4073/4885ESR1 4332/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.